Clinical trials: Airway Assessment
Obstructive Sleep Apnea (OSA)
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy
The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of GZR18 injection in Chinese adult obese patients with moderate-to-severe…
- Trial name
- NCT07501832
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups.
- Trial name
- AEOLUS (NCT07053423)
- Testing
- Dupilumab
- Where
- 85 sites in United States, Argentina and 20 more
- Volunteers
- 218 people
- Sponsor
- Sanofi
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.
Comparison of two asthma treatments by lung function measures.
- Trial name
- NCT00169546
- Testing
- Salmeterol/fluticasone propionate, Fluticasone propionate
- Where
- 2 sites in New Zealand, United Kingdom
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Asthma
Early Airway Response to Allergen in Asthmatics (MK-0000-176)
This study will assess the Early Airway Response (EAR) associated change in forced expiratory volume in one second (FEV1) and plasma 9α-11ß-PGF2 ('9P') after single dose pretreatment of nedocromil, montelukast, and mometasone.
- Trial name
- NCT01061333
- Testing
- Nedocromil, Comparator: Montelukast, Comparator: Mometasone
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.
- Trial name
- NCT00071552
- Testing
- Qvar, Flovent Diskus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Bronchitis, COPD
Gala Treatment for Chronic Bronchitis in Canada
Feasibility trial (FIH) to assess the safety and clinical utility in patients with chronic bronchitis in Canada.
- Trial name
- NCT03385616
- Testing
- Gala Airway Treatment System
- Where
- 3 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Gala Therapeutics, Inc.
Obesity, Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway…
- Trial name
- MARITIME-OSA-1 (NCT07225686)
- Testing
- Maridebart cafraglutide
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
- Trial name
- NCT06994650
- Testing
- HRS9531
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Nasal Septal Deviation, Nasal Airway Obstruction
Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
Pilot study of bioabsorbable implant and delivery device for correction of septal deviation.
- Trial name
- NCT06163404
- Testing
- Implantation of Spirair Nasal Device using the Spirair delivery system.
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Spirair, Inc
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety.
- Trial name
- UNISHAPE-OSA-1 (NCT07767942)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cystic Fibrosis, Motor Neuron Disease
MN4000 for Treatment of CF and MND Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
- Conditions
- Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
- Trial name
- NCT03797677
- Testing
- MN 4000
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Obstructive Sleep Apnea
PAP-NAP Device Clinical Study
This exploratory pilot study will evaluate the usability and short-term tolerability of a novel positive airway pressure (PAP) device in adults during a supervised daytime nap session in a simulated sleep environment.
- Trial name
- NCT07785310
- Testing
- APL Device
- Volunteers
- 10 people
- Sponsor
- ResMed
Chronic Obstructive Pulmonary Disease
NVA237 BID Versus Placebo Twelve-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01715298
- Testing
- NVA237
- Where
- 59 sites in United States
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients
In this study the possible changes in airway geometry and function induced by 6 month oral treatment with Daxas® (roflumilast) will be evaluated.
- Trial name
- NCT01480661
- Testing
- Roflumilast, Functional Respiratory Imaging
- Where
- 2 sites in Belgium
- Volunteers
- 41 people
- Sponsor
- FLUIDDA nv
Nasal Congestion
Study on Hypertonic Saline Nasal Spray
Phytosun decongestant nasal spray is a class I medical device registered in the European Union for the treatment of nasal congestion. The spray contains hypertonic seawater and essential oils.
- Trial name
- PhytosunDecon (NCT02100605)
- Testing
- Phytosun, decongestant, nasal spray
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Omega Pharma
Nasal Obstruction
Treatment of Nasal Airway Obstruction Using the Aerin Medical Device
Evaluation of the Aerin Medical Device used for the treatment of nasal obstruction.
- Trial name
- NCT02914236
- Testing
- Vivaer Stylus
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aerin Medical
Difficult or Failed Intubation, Obesity, Morbid
Evaluation of Preoperative Nasoendoscopy to Predict Difficult Intubation
Despite the availability of different methods for airway assessment, unexpectedly difficult intubations occur at a frequency of up to 15%.
- Trial name
- NCT05043779
- Testing
- Awake Airway Nasoendoscopy
- Where
- Qatar
- Volunteers
- 30 people
- Sponsor
- Hamad Medical Corporation